|Articles|June 12, 2015
- Precision Medicine
- Volume 2
- Issue 1
Nivolumab and Future Biomarkers in NSCLC
Author(s)Roy S. Herbst, MD, PhD
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (medical oncology), professor of Pharmacology, chief, Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital at Yale-New Haven, associate director, Translational Research, Translational Working Group Leader, Thoracic Oncology Program, Yale Cancer Center, discusses the results of the CheckMate-057 trial, which examined nivolumab in patients with NSCLC, and possible biomarkers that could be identified.
Advertisement
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (medical oncology), professor of Pharmacology, chief, Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital at Yale-New Haven, associate director, Translational Research, Translational Working Group Leader, Thoracic Oncology Program, Yale Cancer Center, discusses the results of the CheckMate-057 trial, which examined nivolumab in patients with NSCLC, and possible biomarkers that could be identified.
<<<
Articles in this issue
about 11 years ago
Clinical Validation and Utility of a Liquid Biopsy in NSCLCabout 11 years ago
Significance of the NCI Molecular Analysis for Therapy Choice Programabout 11 years ago
Scoring System May Help Guide Therapy in Triple-Negative Breast CancerAdvertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Advanced Renal Cell Carcinoma: Summarizing a Practical First-Line Treatment Algorithm
2
Long-Term OMNIVORE Data Show Durable Treatment-Free Survival in RCC
3
On-Body Injector Technology Streamlines Subcutaneous Myeloma Therapy
4
First Patients Dosed With TLX597-Tx in Trial for mHSPC
5